Study Shows Cancer Patients Can Benefit from Opioid Switching
Switching from one prescription opioid to another often solves the problem of debilitating side effects or inadequate pain relief, according to a recent study involving a wide range of cancer patients. Opioids are not all the same. And neither are those they are helping. Despite the increasing government restrictions and the frenzy over potential abuse, opioids can be a lifesaver for a mesothelioma patient finding the right fit. “I’ve been through both sides of that switching issue,” said Tim Crisler, a 16-year pleural mesothelioma survivor told The Mesothelioma Center at Asbestos.com. “It worked gr...
Source: Asbestos and Mesothelioma News - November 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Repeated blast model of mild traumatic brain injury alters oxycodone self-administration and drug seeking - Nawarawong NN, Slaker M, Muelbl M, Shah AS, Chiariello R, Nelson LD, Budde MD, Stemper BD, Olsen CM.
Each year, traumatic brain injuries (TBI) affect millions worldwide. Mild TBIs (mTBI) are the most prevalent and can lead to a range of neurobehavioral problems, including substance abuse. A single blast exposure, inducing mTBI alters the medial prefrontal... (Source: SafetyLit)
Source: SafetyLit - November 22, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

FDA Panels Recommend Approval of Abuse-Deterrent IR Oxycodone FDA Panels Recommend Approval of Abuse-Deterrent IR Oxycodone
Two FDA advisory committees voted 10-7 for recommending approval for a new abuse-deterrent formulation of immediate-release (IR) oxycodone to treat adult patients with severe pain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Abuse-Deterrent Oxycodone Ekes Out FDA Panel Win
(MedPage Today) -- 10-7 vote in joint advisory committee meeting favoring MNK-812 approval (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 15, 2018 Category: American Health Source Type: news

New Abuse-Deterrent IR Oxycodone Drug to Be Reviewed
(MedPage Today) -- MNK-812 employs multiple technologies to make snorting painful and injection difficult (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - November 13, 2018 Category: Psychiatry Source Type: news

Blue Cross making changes to opioid policy in 2019
Blue Cross and Blue Shield of Alabama is making changes to the way it handles opioids. Alabama's largest health insurer said it is changing its opioid management strategy for its commercial members in 2019 as part of a larger effort to combat the opioid epidemic. Blue Cross said it will cover Roxybond, the new instant release oxycodone formulation that is considered an “abuse de terrent” by the Food and Drug Administration. Lucemyra, the first non—opioid approved drug to treat the symptoms… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 7, 2018 Category: Pharmaceuticals Authors: Tyler Patchen Source Type: news

Blue Cross making changes to opioid policy in 2019
Blue Cross and Blue Shield of Alabama is making changes to the way it handles opioids. Alabama's largest health insurer said it is changing its opioid management strategy for its commercial members in 2019 as part of a larger effort to combat the opioid epidemic. Blue Cross said it will cover Roxybond, the new instant release oxycodone formulation that is considered an “abuse de terrent” by the Food and Drug Administration. Lucemyra, the first non—opioid approved drug to treat the symptoms… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 7, 2018 Category: Biotechnology Authors: Tyler Patchen Source Type: news

She drank kratom tea while pregnant. Then her newborn went into withdrawal
The woman had used oxycodone for almost a decade but told her doctors she had been sober for two years. She never touched narcotics during her pregnancy, she said, and had completed rehab. (Source: CNN.com - Health)
Source: CNN.com - Health - November 7, 2018 Category: Consumer Health News Source Type: news

Rx Switching at the Pharmacy: What would you say?
Should you substitute  Vigamox with Moxeza? How about Oxycontin with MS Contin? Take our quick, 4-question quiz to find out.  (Source: ConsultantLive)
Source: ConsultantLive - November 1, 2018 Category: Internal Medicine Authors: Alex Evans, PharmD, BCGP Source Type: news

Comparison of Oxycodone and Morphine for Cancer Pain Comparison of Oxycodone and Morphine for Cancer Pain
Do oxycodone and morphine differ significantly in their analgesic efficacy or tolerability when used as first-line therapy for patients with moderate to severe cancer pain?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 31, 2018 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Roxicodone (Oxycodone Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 24, 2018 Category: Drugs & Pharmacology Source Type: news

SpineThera gets a potential suitor: The maker of OxyContin
A non-opioid painkiller being developed by Plymouth-based SpineThera Inc. has caught the eye of Purdue Pharma, the maker of OxyContin, which has signed a deal to give the Connecticut pharmaceutical company the exclusive option to acquire SpineThera. The companies announced the deal, which also includes granting worldwide rights for SpineThera's key SX600 drug to Stamford, Conn.-based Purdue, on Monday. Terms weren't disclosed. “We are committed to alleviating pain through new and innovative… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 23, 2018 Category: Biotechnology Authors: Mark Reilly Source Type: news

U.S. FDA Announces Joint Advisory Committee Review of Mallinckrodt's Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone(R) (Oxycodone Hydrochloride)
Company Seeks Approval of New Drug Application for MNK-812 Through 505(b)2 Regulatory Pathway STAINES-UPON-THAMES, United Kingdom, Oct. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharma... Biopharmaceuticals, Drug Delivery, FDA Mallinckrodt, Roxicodone, Oxycodone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2018 Category: Pharmaceuticals Source Type: news

U.S. hospitals overrun by babies dependent on opioids
(Natural News) Opioids are a class of strong prescription painkillers which are incredibly addictive. Initially prescribed as a pain management tool for cancer sufferers, in the early 1990s drug giant Purdue Pharma started aggressively pitching them to doctors as an effective treatment for chronic pain. In just six years, prescriptions for Purdue’s star product – OxyContin... (Source: NaturalNews.com)
Source: NaturalNews.com - October 2, 2018 Category: Consumer Health News Source Type: news

Percodan (Aspirin and Oxycodone Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2018 Category: Drugs & Pharmacology Source Type: news

Tennessee nurse wrote herself prescriptions for over 10,000 opioids and muscle relaxers
Tennessee nurse Patricia Tillis, 61, had been suspended after writing herself 104 prescriptions over three years. She used a pre-signed prescription pad to give herself oxycodone and Soma. (Source: the Mail online | Health)
Source: the Mail online | Health - September 17, 2018 Category: Consumer Health News Source Type: news

Oregon AG Rosenblum accuses OxyContin maker of deceptive marketing
Purdue Pharma targeted Oregon seniors in a deceptive marketing campaign for the opioid painkiller OxyContin and lied to the Oregon Board to Pharmacy to boost its profits, Attorney General Ellen Rosenblum alleged in a lawsuit filed Thursday. Purdue misrepresented the risks and benefits of the drug and engaged in a pattern of racketeering and other misleading activity, according to the complaint filed in Multnomah County Circuit Court. Rosenblum contends Purdue violated a stipulated Oregon judgment… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 14, 2018 Category: American Health Authors: Elizabeth Hayes Source Type: news

Is extra monitoring a solution for opioid abuse? Proposal would send high-dose users to special pain units
(Natural News) British doctors are calling for stricter rules in the management of painkillers in order to fight the opioid addiction epidemic. These medical professionals are now suggesting that patients who are given highly powerful opioids such as oxycodone and tramadol should be referred to special pain units who would then conduct monthly reviews. The... (Source: NaturalNews.com)
Source: NaturalNews.com - September 11, 2018 Category: Consumer Health News Source Type: news

Elderly Couple Who Ran Manhattan'Pill Mill' Headed to Jail Elderly Couple Who Ran Manhattan'Pill Mill' Headed to Jail
Rogelio Lucas and his wife and office manager are sentenced to jail for flooding New York City streets with more than 3 million oxycodone pills worth nearly $80 million.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Elderly Doctor, Wife Who Ran NYC'Pill Mill' Headed to Jail Elderly Doctor, Wife Who Ran NYC'Pill Mill' Headed to Jail
Rogelio Lucas and his wife and office manager are sentenced to jail for flooding New York City streets with more than 3 million oxycodone pills worth nearly $80 million.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Oxycontin ’ s Maker Now Selling Drug to Curb Opioid Addiction
New anti - addiction drug is fast - acting form of buprenorphine, which helps control drug cravings (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - September 11, 2018 Category: Psychiatry Tags: Pharmacy, Psychiatry, Anesthesiology & amp; Pain, Institutional, Source Type: news

OxyContin maker reportedly patents drug to treat opioid addiction
Purdue Pharma has reportedly received a patent for a medication to fight opioid addiction. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 10, 2018 Category: Pharmaceuticals Source Type: news

Oxycontin Maker Selling Opioid Addiction Drug, Too
The new anti-addiction drug is a fast-acting form of buprenorphine, which helps control drug cravings, CBS News reported. (Source: WebMD Health)
Source: WebMD Health - September 10, 2018 Category: Consumer Health News Source Type: news

Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
MONDAY, Sept. 10, 2018 -- Purdue Pharma, the maker of Oxycontin who some have blamed for the epidemic of opioid painkiller addictions, has patented a medicine aimed at curbing those disorders. The new anti-addiction drug is a fast-acting form of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2018 Category: Pharmaceuticals Source Type: news

Health Highlights: Sept. 10, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction Purdue Pharma, the maker of Oxycontin who some have blamed for the epidemic of opioid... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 10, 2018 Category: General Medicine Source Type: news

Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
Title: Oxycontin's Maker Now Selling Drug to Curb Opioid AddictionCategory: Health NewsCreated: 9/10/2018 12:00:00 AMLast Editorial Review: 9/10/2018 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - September 10, 2018 Category: Anesthesiology Source Type: news

How Purdue’s ‘one-two’ punch fuelled the opioids market
Accused of exaggerating the benefits of OxyContin, the company’s owners had a bigger share than realised (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 10, 2018 Category: Pharmaceuticals Source Type: news

OxyContin maker gets patent to treat opioid addiction
Purdue Pharma, accused of fueling the opioid abuse epidemic, now stands to profit from treating it (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 7, 2018 Category: Consumer Health News Source Type: news

Opioid Maker to Pay for Overdose Antidote Development
THURSDAY, Sept. 6, 2018 -- A $3.4 million grant to help a non-profit company develop a less expensive opioid overdose antidote was announced by Purdue Pharma, which makes the opioid painkiller OxyContin. The grant is being given to Pittsburgh-based... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 6, 2018 Category: Pharmaceuticals Source Type: news

BlueCross of Tennessee will stop covering OxyContin in 2019
Tennessee's largest health insurer will stop covering OxyContin prescriptions as part of an effort to combat opioid addiction (Source: ABC News: Health)
Source: ABC News: Health - September 6, 2018 Category: Consumer Health News Tags: Health Source Type: news

Opioid Maker to Pay for Overdose-Antidote Development
A company whose prescription opioid marketing practices are being blamed for sparking the addiction and overdose crisis says it's helping to fund an effort to make a lower-cost overdose antidote. OxyContin maker Purdue Pharma announced Wednesday that it's making a $3.4 million grant to Harm Reduction Therapeutics, a Pittsburgh-based nonprofit, to help develop a low-cost naloxone nasal spray. The announcement comes as lawsuits from local governments blaming Purdue, based in Stamford, Connecticut, and other companies in the drug industry for using deceptive marketing practices to encourage heavy prescribing of the powerful a...
Source: JEMS Patient Care - September 6, 2018 Category: Emergency Medicine Tags: Patient Care News Source Type: news

Opioid Maker to Pay for Overdose-Antidote Development
A company whose prescription opioid marketing practices are being blamed for sparking the addiction and overdose crisis says it's helping to fund an effort to make a lower-cost overdose antidote. OxyContin maker Purdue Pharma announced Wednesday that it's making a $3.4 million grant to Harm Reduction Therapeutics, a Pittsburgh-based nonprofit, to help develop a low-cost naloxone nasal spray. The announcement comes as lawsuits from local governments blaming Purdue, based in Stamford, Connecticut, and other companies in the drug industry for using deceptive marketing practices to encourage heavy prescribing of the powerful a...
Source: JEMS: Journal of Emergency Medical Services News - September 6, 2018 Category: Emergency Medicine Tags: Patient Care News Source Type: news

Health Highlights: Sept. 6, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: OxyContin Maker Gives $3.4 Million to Help Develop Cheaper Opioid Overdose Antidote A $3.4 million grant to help a nonprofit company develop a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2018 Category: General Medicine Source Type: news

The Latest: Lawyer questions drug company motive with grant
With lawsuits mounting, maker of OxyContin provides grant for nonprofit pharmaceutical company to speed development of lower-cost overdose antidote (Source: ABC News: Health)
Source: ABC News: Health - September 5, 2018 Category: Consumer Health News Tags: Health Source Type: news

Major opioid maker to pay for overdose-antidote development
With lawsuits mounting, maker of OxyContin provides grant for nonprofit pharmaceutical company to speed development of lower-cost overdose antidote (Source: ABC News: Health)
Source: ABC News: Health - September 5, 2018 Category: Consumer Health News Tags: Health Source Type: news

The domino effect of the opioid epidemic: Thousands of American kids are being forced into foster care due to parents’ addiction
(Natural News) According to a new study, the opioid crisis is now affecting children who are being dragged from their homes and into foster care because of parental neglect caused by addiction. The study authors note that an addiction to prescription painkillers (e.g. oxycodone and morphine) is partly responsible for the sudden increase in deaths caused... (Source: NaturalNews.com)
Source: NaturalNews.com - August 31, 2018 Category: Consumer Health News Source Type: news

August 28, 2018: Providence Nurse Sentenced for Tampering with Oxycodone
(Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - August 30, 2018 Category: Medical Law Source Type: news

Purdue Pharma's Sales Pitch Downplayed Risks of Opioid Addiction Purdue Pharma's Sales Pitch Downplayed Risks of Opioid Addiction
Two decades ago, Purdue Pharma produced thousands of brochures and videos that urged patients with chronic pain to ask their physicians for opioids such as OxyContin, arguing that concerns over addiction and other dangers from the drugs were overblown.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Exclusive: OxyContin maker Purdue taps financial restructuring adviser - sources
OxyContin maker Purdue Pharma LP has tapped law firm Davis Polk& Wardwell LLP for financial restructuring advice, as its potential liabilities swell with a wave of lawsuits over the opioid addiction epidemic sweeping the United States, people familiar with the matter said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Trump calls for lawsuit against some opioid companies
Trump administration also wants to cut production quotas of most-abused opioids, including oxycodone and fentanyl. (Source: CBC | Health)
Source: CBC | Health - August 16, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Percocet (oxycodone and acetaminophen, Roxicet, Tylox, Oxycet)
Title: Percocet (oxycodone and acetaminophen, Roxicet, Tylox, Oxycet)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/16/2018 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - August 16, 2018 Category: Anesthesiology Source Type: news

New York Sues OxyContin Maker Purdue Pharma Over Opioids New York Sues OxyContin Maker Purdue Pharma Over Opioids
New York state on Tuesday said it has sued Purdue Pharma LP, accusing the OxyContin (oxycodone hydrochloride) maker of widespread fraud and deception in the marketing of opioid products, contributing to a nationwide epidemic that has killed thousands.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

New York sues OxyContin maker Purdue Pharma over opioids
New York state on Tuesday said it has sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioid products, contributing to a nationwide epidemic that has killed thousands. (Source: Reuters: Health)
Source: Reuters: Health - August 14, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New York state sues Purdue
The state has thrown its hat in the ring with at least 26 more states to sue the OxyContin maker over the opoids (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 14, 2018 Category: Pharmaceuticals Source Type: news

Looking Past Dementia Reveals Hidden Life Threats
You and your partner just went into service when the radio begins to chirp, “Unit 10, respond Code 3 to Seniorville Nursing Facility for an 85-year-old female with altered mental status.” You kick the truck into gear and are quickly on scene. The patient’s nurse tells you that the patient has been at the facility for three days for rehabilitation after a hip replacement that occurred one week ago. The patient was initially OK, but over the last 24 hours has been anorexic (i.e., not eating), agitated and is refusing to allow healthcare providers to assess her. Her condition has become so severe that they b...
Source: JEMS Patient Care - August 13, 2018 Category: Emergency Medicine Authors: Joseph K. Mesches, NRP, FP-C Tags: Exclusive Articles Patient Care Source Type: news

How Opioid Drugmakers Tried to Exploit OxyContin Debacle
(MedPage Today) -- Internal Purdue documents describe rivals'marketing tactics (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 7, 2018 Category: Psychiatry Source Type: news

FDA rejects Pain Therapeutics' lead drug, shares tumble
Pain Therapeutics Inc. is undergoing a major overhaul after the U.S. Food and Drug Administration rejected its new drug application for Remoxy, an extended-release and tamper-resistant version of the painkiller oxycodone. The Austin-based drugmaker said Monday in a securities filing it would shift its focus from painkillers to treatments for Alzheimer's disease. That comes after Pain Therapeutics (Nasdaq: PTIE) heard from the FDA that Remoxy data "do not support the conclusion" that its benefits… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 7, 2018 Category: Pharmaceuticals Authors: Will Anderson Source Type: news

FDA Turns Down Abuse-Deterrent Remoxy ER for Pain FDA Turns Down Abuse-Deterrent Remoxy ER for Pain
The FDA has followed its Advisory Committee's earlier recommendation and nixed approval of abuse-deterrent oxycodone extended-release capsules (Remoxy ER) for severe pain.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 6, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Nonfiction: The Worst Drug Crisis in American History
Beth Macy ’ s “ Dopesick ” describes the opioid epidemic that is killing thousands every year. (Source: NYT Health)
Source: NYT Health - July 31, 2018 Category: Consumer Health News Authors: JESSICA BRUDER Tags: Books and Literature Opioids and Opiates Macy, Beth Dopesick (Book) OxyContin (Drug) Drugs (Pharmaceuticals) Appalachian Region Source Type: news